Cue Biopharma names Lucinda Warren as chief financial and business officer Feb 12, 2026 08:02AM
Cue Biopharma Inc. (CUE) announces departure of Chief Medical Officer Nov 20, 2025 04:04PM
Cue Biopharma (CUE) An Attractive Investment Opportunity - Citizens Nov 18, 2025 04:30AM
ImmunoScape licenses Cue Biopharma technology for solid tumor therapy Nov 13, 2025 01:11PM
Cue Biopharma, Inc. (CUE) Tops Q3 EPS by 2c Nov 13, 2025 06:27AM


Sep 29, 2025 09:00AM Cue Biopharma names Usman Azam as new CEO effective September 29
Aug 25, 2025 06:35AM Lucid Capital Markets Starts Cue Biopharma (CUE) at Buy, 'attractive long-term growth story, with first-in-class assets and a validated platform'
Aug 12, 2025 05:47PM Cue Biopharma, Inc. (CUE) Tops Q2 EPS by 5c
Jul 1, 2025 04:05PM Cue Biopharma Inc. (CUE) Provides Update CUE-101
Jun 24, 2025 04:48PM Cue Biopharma Inc. (CUE) Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401
May 30, 2025 05:01AM Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
May 13, 2025 07:02AM Cue Biopharma, Inc. (CUE) Misses Q1 EPS by 1c
Apr 21, 2025 04:23AM Citizens JMP Reiterates Market Outperform Rating on Cue Biopharma (CUE)
Apr 15, 2025 04:09AM Citizens JMP Reiterates Market Outperform Rating on Cue Biopharma (CUE)
Apr 14, 2025 05:06PM Cue Biopharma Inc. (CUE) announces public offering of common stock
Apr 14, 2025 05:00PM Boehringer Ingelheim and Cue Biopharma (CUE) partner to develop next-generation treatment for autoimmune and inflammatory diseases
Apr 2, 2025 04:38AM Citizens JMP Reiterates Market Outperform Rating on Cue Biopharma (CUE)
Nov 15, 2024 08:59AM Cue Biopharma (CUE) PT Lowered to $4 at Jefferies
Nov 15, 2024 07:07AM Cue Biopharma, Inc. (CUE) Tops Q3 EPS by 1c
Nov 8, 2024 01:31PM Cue Biopharma (CUE) Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102
Sep 27, 2024 06:04AM Cue Biopharma Inc. (CUE) Prices $12M Offering at $0.50/sh
Sep 26, 2024 04:27PM Cue Biopharma (CUE) Announces Proposed Public Offering
Sep 9, 2024 08:03AM Cue Biopharma Inc. (CUE) Appoints Lucinda Warren as Chief Business Officer
Aug 20, 2024 07:32AM Cue Biopharma (CUE) PT Lowered to $4 at Stifel
Aug 20, 2024 05:16AM Piper Sandler Reiterates Overweight Rating on Cue Biopharma (CUE)
Aug 19, 2024 04:20PM Cue Biopharma, Inc. (CUE) Tops Q2 EPS by 8c
Jul 26, 2024 07:44AM Cue Biopharma (CUE) PT Lowered to $3 at Piper Sandler
Jul 25, 2024 04:05PM Cue Biopharma (CUE) Announces Strategic Prioritization of Autoimmune Programs